

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 November 2022 (10.11.2022)



(10) International Publication Number
WO 2022/235882 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) *A61P 29/00* (2006.01)
A61K 47/24 (2006.01) *A61P 37/00* (2006.01)
A61K 47/12 (2006.01) *C07K 16/24* (2006.01)
A61K 47/10 (2006.01) *A61K 39/00* (2006.01)
A61K 9/08 (2006.01)

KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2022/027794

(22) International Filing Date:

05 May 2022 (05.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/184,333 05 May 2021 (05.05.2021) US

(71) Applicant: **I2O THERAPEUTICS, INC.** [US/US]; 13250 Via Arriba Drive, Saratoga, California 95070 (US).

(72) Inventors: **BROWN, Tyler**; 13250 Via Arriba Drive, Saratoga, California 95070 (US). **IBSEN, Kelly**; 13250 Via Arriba Drive, Saratoga, California 95070 (US).

(74) Agent: **HOSTETLER, Michael**; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: IONIC LIQUID FORMULATIONS FOR TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES




FIG. 4A

(57) Abstract: The present disclosure provides compositions comprising a therapeutic agent and at least one ionic liquid and the use thereof for treating conditions or diseases in a subject. Specifically, the present disclosure provides a method of treating inflammatory and autoimmune diseases by delivering the ionic liquid formulations comprising choline as a cation and various anions; and a therapeutic antibody or an antibody reagent to a subject.

WO 2022/235882 A1